X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2023/12/15/2797014/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-Clinical-Trial-of-Samuraciclib-in-Combination-with-Fulvestrant-in-Patients-with-Advanced-HR-HER2-Breast-Cancer.html
https://www.gene.com/media/press-releases/15012/2023-12-08/genentechs-inavolisib-combination-reduce
https://www.globenewswire.com//news-release/2023/11/28/2786889/0/en/eFFECTOR-Receives-U-S-FDA-Fast-Track-Designation-for-Zotatifin-in-Combination-with-Fulvestrant-and-Abemaciclib-for-Treatment-of-ER-HER2-Advanced-Metastatic-Breast-Cancer.html
https://www.contractpharma.com/contents/view_breaking-news/2023-11-20/astex-earns-astrazeneca-milestone-for-truqap-approval/?widget=listSection
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-astrazenecas-breast-cancer-drug-combination-2023-11-16/
https://www.onclive.com/view/nda-submission-planned-for-ea-114-in-metastatic-breast-cancer-following-positive-type-c-meeting-with-fda
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215169
https://www.onclive.com/view/sonia-trial-suggests-second-line-use-may-be-optimal-for-cdk4-6-inhibitors-in-hr-her2-breast-cancer
https://www.clinicaltrialsarena.com/news/effector-updates-cancer-combo-expansion/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-drug-to-treat-breast-cancer/articleshow/96508925.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215077
https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer.html
https://endpts.com/pfizer-backs-60m-infusion-into-carrick-teams-up-on-breast-cancer-treatment/
https://www.businesswire.com/news/home/20220920005346/en/Puma-Biotechnology-Announces-Exclusive-License-Agreement-with-Takeda-for-the-Development-and-Commercialization-of-Alisertib-an-Investigational-Aurora-Kinase-A-Inhibitor
https://www.globenewswire.com/news-release/2022/09/13/2515038/0/en/Sermonix-Pharmaceuticals-Announces-Results-of-Phase-2-Study-of-Lasofoxifene-vs-Fulvestrant-in-Postmenopausal-Women-With-Locally-Advanced-or-Metastatic-ER-HER2-Breast-Cancer-and-an-.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-24-2022-1661335123.pdf
https://www.pharmatimes.com/news/nice_recommends_novartis_piqray_therapy_1452254
https://www.expresspharma.in/new-novartis-data-show-piqray-effectiveness-across-key-biomarkers-in-patients-with-hr-her2-metastatic-breast-cancer/
https://www.clinicaltrialsarena.com/news/laekna-breast-cancer-trial/
https://www.fiercebiotech.com/biotech/weeks-after-sanofi-flop-roches-rival-oral-serd-flunks-phase-2-breast-cancer-test
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214682
https://www.novartis.co.uk/news/media-releases/mhra-approves-licence-extension-novartis%27-targeted-therapy-advanced-breast
https://www.globenewswire.com/news-release/2021/10/27/2321601/0/en/Context-Therapeutics-and-Wisconsin-Oncology-Network-Announce-First-Patient-Dosed-in-Phase-2-Trial-of-ONA-XR-in-Metastatic-Breast-Cancer.html
https://www.fiercebiotech.com/biotech/cedilla-tops-off-series-b-additional-25m-to-test-drugs-mesothelioma-certain-breast-cancers
https://www.fiercebiotech.com/biotech/menarini-chased-by-three-big-pharmas-records-win-breast-cancer-phase-3-plots-path-to-fda
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-29-2021-1632907538.pdf
https://www.globenewswire.com/news-release/2021/09/16/2298249/0/en/Carrick-Therapeutics-Presents-Encouraging-Initial-Efficacy-for-Samuraciclib-CT-7001-in-Combination-with-Fulvestrant-in-Advanced-HR-HER2-Breast-Cancer-Patients-at-ESMO-Congress-2021.html
http://www.pharmatimes.com/news/fda_fast_tracks_breast_cancer_candidate_samuraciclib_1375147
https://www.business-standard.com/article/news-cm/dr-reddy-s-announces-the-launch-of-fulvestrant-injection-120090800169_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209246
http://www.pharmatimes.com/news/eu_regulators_approve_novartis_breast_cancer_combo_1346033
http://www.pharmatimes.com/news/novartis_kisquali_bests_az_faslodex_in_breast_cancer_trial_1319827
http://www.pharmafile.com/news/534514/pfizer-s-ibrance-approved-nice-be-added-cancer-drugs-fund
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209714
https://endpts.com/novartis-eli-lilly-marquee-positive-survival-data-for-cdk-4-6-franchises-but-can-they-actually-beat-pfizers-blockbuster/
https://www.prnewswire.com/news-releases/pii-to-manufacture-fda-approved-hormone-therapy-injection-drug-product-300922043.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207754
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205871
https://www.pharmacytimes.com/resource-centers/womens-health/fda-approves-generic-fulvestrant-injection-for-advanced-breast-cancer
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208811
http://www.pharmatimes.com/news/nice_u-turn_for_kisquali_in_breast_cancer_1294696
https://www.fiercepharma.com/marketing/novartis-kisqali-trailing-lilly-s-verzenio-nabs-restricted-nice-backing-breast-cancer
Market Place
Share 
